Imperial College London

Jiri Pavlu

Faculty of MedicineDepartment of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

133 results found

Pavlu J, Szydlo RM, Goldman JM, Apperley JFet al., 2011, Three decades of transplantation for chronic myeloid leukemia: what have we learned?, BLOOD, Vol: 117, Pages: 755-763, ISSN: 0006-4971

Journal article

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni Let al., 2011, Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors, Journal of Clinical Oncology

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.Patients and Methods We analyzed 282 patients with CML-CP who received imatinib 400 mg/d as first-line therapy followed by dasatinib or nilotinib if treatment with imatinib failed. We used a receiver operating characteristic curve to identify the cutoffs in transcript levels at 3, 6, and 12 months that would best predict patient outcome. We validated our findings in an independent cohort of 95 patients treated elsewhere.Results Patients with transcript levels of more than 9.84% (n = 68) at 3 months had significantly lower 8-year probabilities of OS (56.9% v 93.3%; P < .001), progression-free survival, cumulative incidence of complete cytogenetic response, and complete molecular response than those with higher transcript levels. Similarly, transcript levels of more than 1.67% (n = 87) at 6 months and more than 0.53% (n = 93) at 12 months identified high-risk patients. However, transcript levels at 3 months were the most strongly predictive for the various outcomes. When we compared OS for the groups defined molecularly at 6 and 12 months with the usual cytogenetic milestones, categorization by transcript numbers was the only independent predictor for OS (relative risk, 0.207; P < .001 and relative risk, 0.158; P < .001, respectively).Conclusion A single measurement of BCR-ABL1 transcripts performed at 3 months is the best way to identify patients destined to fare poorly, thereby allowing early clinical intervention.

Journal article

Pavlu J, Shah R, Auner HW, Milojkovic D, Sargent DMJ, MacDonald ARDH, Kanfer EJ, Rezvani K, Dazzi F, Apperley JMGJF, Szydlo RMet al., 2010, Preconditioning Level of C Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Pages: 1433-1434, ISSN: 0006-4971

Conference paper

Pavlu J, Shah R, Auner HW, Milojkovic D, Marin D, Sargent J, Rahemtulla A, MacDonald DH, Kanfer EJ, Rezvani K, Dazzi F, Goldman JM, Apperley JF, Szydlo RMet al., 2010, Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 1433-1434, ISSN: 0006-4971

Conference paper

Holroyd A, Phillips E, Szydlo R, Marin D, Foroni L, Khorashad J, Milojkovic D, Kanfer EJ, Dazzi F, MacDonald DH, Rahemtulla A, McLornan D, Gabriel IH, Pavlu J, Sargent J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 1445-1445, ISSN: 0006-4971

Conference paper

Chaidos A, Szydlo RM, Kanfer EJ, Dazzi F, MacDonald DH, Marin D, Milojkovic D, Pavlu J, Davis J, Rezvani K, Rahemtulla A, Roberts I, Apperley JF, Karadimitris Aet al., 2010, High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts., 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 1051-1052, ISSN: 0006-4971

Conference paper

De Lavallade H, Garland PL, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo RM, Kanfer EJ, McDonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Alsuliman A, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, 2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies Requirement for Repeated Dosing to Optimize Seroprotec, Pages: 297-298, ISSN: 0006-4971

Conference paper

Holroyd A, Phillips E, Szydlo R, Mann D, Foroni L, Khorashad J, Milojkovic D, Kanfer EJ, Dazzi F, MacDonald DH, Rahemtulla A, McLornan D, Gabriel IH, Pavlu J, Sargent J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chrome Myeloid Leukemia, Pages: 1445-1445, ISSN: 0006-4971

Conference paper

de Lavallade H, Garland PL, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo RM, Kanfer EJ, McDonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Alsuliman A, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, 2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 297-298, ISSN: 0006-4971

Conference paper

Naresh KN, Pavlu J, 2010, Plasmacytoid dendritic cell nodules in bone marrow biopsies of chronic myelomonocytic leukemia, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 85, Pages: 893-893, ISSN: 0361-8609

Journal article

Pavlu J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RMet al., 2010, Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase, BLOOD, Vol: 115, Pages: 4018-4020, ISSN: 0006-4971

Journal article

Garland P, de Lavallade H, Sekine T, Stringaris K, Loucaides E, Howe K, Kanfer E, Marin D, Apperley J, Milojkovic D, Macdonald D, Rahemtulla A, Pavlu J, Gabriel I, Khoder A, Alsuliman A, Bazeos A, Szydlo R, Cooper N, Rezvani Ket al., 2010, Severe 2009 H1N1 influenza in patients with haematological malignancies, 50th Annual Scientific Meeting of the British-Society-for-Haematology, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 47-47, ISSN: 0007-1048

Conference paper

Pavlu J, Kew A, Taylor-Roberts B, Auner H, Kanfer E, MacDonald D, Marin D, Milojkovic D, Rahemtulla A, Rezvani K, Goldman J, Apperley J, Szydlo Ret al., 2010, Optimizing patient selection for myeloablative allogeneic haemopoietic cell transplantation in chronic myeloid leukaemia in chronic phase, 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Publisher: NATURE PUBLISHING GROUP, Pages: S239-S239, ISSN: 0268-3369

Conference paper

Pavlu J, Auner H, Ellis S, Szydlo R, Giles C, McLornan D, Contento A, Rahemtulla A, Apperley J, Naresh K, MacDonald D, Kanfer Eet al., 2010, LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre, BONE MARROW TRANSPLANTATION, Vol: 45, Pages: S255-S255, ISSN: 0268-3369

Journal article

Porkka K, Pavlu J, Contento A, Mustjoki S, Olavarria E, Apperley Jet al., 2010, Tyrosine kinase inhibitor therapy is associated with a low risk of cytomegalovirus reactivation after allogeneic haematopoietic stem cell transplantation, 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Publisher: NATURE PUBLISHING GROUP, Pages: S38-S38, ISSN: 0268-3369

Conference paper

Auner H, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, Chaidos A, McLornan D, Giles C, Bua M, Apperley J, Rahemtulla Aet al., 2010, High rate of stem cell mobilization failure after thalidomide and cyclophosphamide induction therapy for myeloma, BONE MARROW TRANSPLANTATION, Vol: 45, Pages: S21-S21, ISSN: 0268-3369

Journal article

Khalique Z, Pavlu J, Lefroy D, Layton Met al., 2010, Erythrocytapheresis in the prevention of recurrent myocardial infarction in sickle cell disease, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 85, Pages: 91-91, ISSN: 0361-8609

Journal article

Pavlu J, Marin D, 2009, Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials, CLINICAL LYMPHOMA & MYELOMA, Vol: 9, Pages: 417-424, ISSN: 1557-9190

Journal article

Chaidos A, Giles C, Auner HW, Bua M, Pavlu J, Smith E, Kanfer E, MacDonald D, Apperley JF, Rahemtulla Aet al., 2009, Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma, 51st Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 507-507, ISSN: 0006-4971

Conference paper

Auner HW, Owiti H, Giles C, Pavlu J, MacDonald D, Kanfer E, Apperley JF, Rahemtulla Aet al., 2009, Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma., 51st Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 708-709, ISSN: 0006-4971

Conference paper

Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, Apperley JF, Rahemtulla Aet al., 2009, The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure, 51st Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 844-844, ISSN: 0006-4971

Conference paper

Pavlu J, Kew A, Taylor-Roberts B, Auner H, Goldman J, Apperley J, Szydlo Ret al., 2009, Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia, 51st Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 1317-1317, ISSN: 0006-4971

Conference paper

Pavlu J, Auner H, Szydlo R, Olavarria E, Giles C, Klammer M, Kew A, Milojkovic D, Gabriel I, Rezvani K, Dazzi F, Marin D, Goldman J, Apperley Jet al., 2009, Allogeneic myeloablative haematopoietic stem cell transplantation for chronic myeloid leukaemia in the imatinib era, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S49-S49, ISSN: 0268-3369

Conference paper

Auner H, Giles C, Pavlu J, Olavarria E, Macdonald D, Kanfer E, Apperley J, Rahemtulla Aet al., 2009, Ethnicity and autologous stem cell transplantation in myeloma, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S148-S148, ISSN: 0268-3369

Conference paper

Auner HW, Giles C, Pavlu J, Macdonald D, Kanfer E, Olavarria E, Apperley J, Rahemtulla Aet al., 2009, Ethnicity and Myeloma: Experience of a Large UK Stem Cell Transplantation Center, Publisher: CIG MEDIA GROUP, LP, Pages: S84-S84, ISSN: 1557-9190

Conference paper

Bayley J, Pavlů J, Thompson M, 2009, Striking bone marrow plasmacytosis in a patient with sickle cell anaemia., Br J Haematol, Vol: 144

Journal article

Marin D, Milojkovic D, Olavarria E, Khorashad JS, de lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JFet al., 2008, European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor, BLOOD, Vol: 112, Pages: 4437-4444, ISSN: 0006-4971

Journal article

Klammer M, Giles C, Reid AG, Ross FM, Szydlo RM, Pavlu J, Apperley JF, Rahemtulla Aet al., 2008, Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma, 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 1140-1140, ISSN: 0006-4971

Conference paper

Pavlu J, Klammer M, Gabriel I, Szydlo R, Olavarria E, Milojkovic D, Kew A, Rezvani K, Dazzi F, Marin D, Goldman J, Apperley Jet al., 2008, Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era., 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 357-357, ISSN: 0006-4971

Conference paper

Milojkovic D, Bua M, Apperley JF, Kozlowski K, Sorori J, Foroni L, Reid A, Pavlu J, Rezvani K, Dazzi F, Olavarria E, Klammer M, Goldman JM, Marin Det al., 2008, Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival, 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 129-129, ISSN: 0006-4971

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00618900&limit=30&person=true&page=4&respub-action=search.html